Contact
searchSearch
HMP Global

Interventional Oncology

Features

Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management
Michael Pishvaian headshot
Interview
Intra-Arterial Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
New Technique
Preoperative Devascularization of Large Neck Tumors Encasing the Internal Carotid Artery Using Hybrid Trapping Technique
06/08/2026
Rajat Singhal, DM, DNB, FRCR, EBIR; Rajchandra Singh Kharayat, DM, DNB; L. Samuel Prabhu Mithra, MCh, MS; Deepak Selvaraj, MCh, MS, MRCS; Shyamkumar Nidugala Keshava, MBBS, DMRD, DNB, FRCR, FRANZCR
The authors describe a novel “technique of hybrid trapping” in a 32-year-old man with a Shamblin III carotid body tumor encasing the internal carotid artery.
The authors describe a novel “technique of hybrid trapping” in a 32-year-old man with a Shamblin III carotid body tumor encasing the internal carotid artery.
The authors describe a novel...
06/08/2026
Vascular Disease Management
Histotripsy
Histotripsy Adoption in Interventional Oncology Presents Opportunities and Challenges in the United Kingdom
06/03/2026
Laura Simson, MA
06/03/2026
Vascular Disease Management
Clinical Trials
Surrogate Endpoints Remain a Challenge in Interventional Oncology Trials
05/12/2026
Laura Simson, MA
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined...
05/12/2026
Vascular Disease Management
Novel Local Therapies
Pulsed Electric Field Ablation Plus SBRT Preserves Quality of Life in Lung Tumors
04/13/2026
Laura Simson, MA
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study...
04/13/2026
Vascular Disease Management
AML TUMORS
Fluidx Medical Announces First Patient Treated with Novel Embolic Gel
04/01/2026
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to...
04/01/2026
Vascular Disease Management

Videos

Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Michael Pishvaian headshot
Interview
Intra-Arterial Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
AI in IO title slide
Video
Advancing AI in IO: Improving Research Quality, Clinical Outcomes, and Patient Care
03/13/2026
Dania Daye, MD, PhD
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in artificial intelligence (AI) studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need...
03/13/2026
Vascular Disease Management
Stumetz headshot
CIO 2025
Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes
11/25/2025
Kyle S. Stumetz, DO; Laura Simson, MA
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the...
11/25/2025
Vascular Disease Management
Dr Prologo
Sponsored Video
Dual-Level Kyphoplasty With OsteoCool 2.0: Simultaneous Ablation and Cementation Guided by Dr Prologo
09/26/2025
J. David Prologo, MD, FSIR
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a groundbreaking look at a dual-level kyphoplasty procedure using the OsteoCool 2.0 system. This exclusive video captures real-time ablation and cement injection at two vertebral levels with 10-gauge cannulas, complete...
Join Dr Prologo for a...
09/26/2025
Vascular Disease Management
JLevy headshot
Video
Percutaneous Ablation for Vertebral Metastases
08/11/2025
Jason Levy, MD, FSIR
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the clinical considerations, procedural techniques, and the ongoing evidence in the use of percutaneous ablation for treating vertebral metastases.
Dr Jason Levy discusses the...
08/11/2025
Vascular Disease Management
McArthur image
Video
Perioperative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-Negative Breast Cancer
06/26/2025
Heather McArthur, MD, MPH
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about her work examining the impact of perioperative cryoablation and immune checkpoint inhibition on 3-year event-free survival in women with TNBC after taxane-based neoadjuvant chemotherapy.
Dr Heather McArthur speaks about...
06/26/2025
Vascular Disease Management
Dr Setayesh Sotoudehnia
Video
Making the Impossible Possible: MR-Guided Interventional Oncology
03/27/2025
Setayesh Sotoudehnia, MD
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh Sotoudehnia of Mayo Clinic Rochester speaks about her research on MR-guided procedures, her GCAW Award, and the advancement of women in the field of interventional radiology.
Ahead of SIR 2025, Dr Setayesh...
03/27/2025
Vascular Disease Management
Dr Parikh
ISET 2025
The Current Role of PAE in the Management of Prostate Cancer
03/18/2025
Nainesh Parikh
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video from ISET2025, interventional radiologist Dr Nainesh Parikh discusses his presentation on the benefits of prostatic artery embolization in the treatment of prostate cancer.
In this video from ISET2025,...
03/18/2025
Vascular Disease Management
Dr Wiechmann
OBL Corner
Why Embolotherapy Is Ideal for the Office-based Lab
03/10/2025
Bret N. Wiechmann, MD, FSIR, FAHA
Dr Bret Wiechmann reviews a presentation that he gave at GEST 2024, which explains how the OBL environment is a good fit for embolotherapy.
Dr Bret Wiechmann reviews a presentation that he gave at GEST 2024, which explains how the OBL environment is a good fit for embolotherapy.
Dr Bret Wiechmann reviews a...
03/10/2025
Vascular Disease Management
Ghassan Abou-Alfa headshot
ASCO 2026
Immunotherapy Plus TACE Emerges as a New Option for Intermediate-Stage Hepatocellular Carcinoma
07/13/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses phase 3 EMERALD-3 results showing that adding STRIDE (tremelimumab plus durvalumab) to transarterial chemoembolization significantly improved progression-free survival in patients with unresectable...
Ghassan Abou-Alfa, MD, discusses...
07/13/2026
Vascular Disease Management
Michael Pishvaian headshot
Interview
Intra-Arterial Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
06/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
06/15/2026
Vascular Disease Management
Dr Kak Khee Yeung speaks at ISET 2026.
ISET 2026
Can AI Be of Value in Predicting Type B Dissection Progression Over Time?
04/16/2026
Kak Khee Yeung, MD, PhD
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD, explores the potential role of AI in predicting the progression of Type B aortic dissection over time.
Kak Khee Yeung, MD, PhD,...
04/16/2026
Vascular Disease Management
Dr Mouawad speaks at ISET 2026
ISET 2026
Advancing Thrombectomy and Autologous Blood Reinfusion for Pulmonary Embolism Treatment: Results from the AVENTUS Pivotal Study
04/09/2026
Nicolas J. Mouawad, MD, MPH, MBA
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results of the AVENTUS pivotal trial.
Dr Mouawad discusses the results...
04/09/2026
Vascular Disease Management
Dr S Jay Mathews speaks at ISET 2026
ISET 2026
Retrievable Scaffold Therapy: Results From Trials
04/07/2026
S. Jay Mathews, MD, MS, FACC, FSCAI
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest...
04/07/2026
Vascular Disease Management
Dr Mary Costantino speaks at ISET 2026.
ISET 2026
Uterine Fibroid Embolization in the OBL: Patient Selection and Workflow Optimization
04/02/2026
Mary Costantino, MD, FSIR
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical...
04/02/2026
Vascular Disease Management
Dr Salazar speaks at ISET 2026
ISET 2026
Venous Valve Technology: When Will It Be Standard of Care?
04/01/2026
Gloria Salazar, MD, FSIR
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current...
04/01/2026
Vascular Disease Management
Dr Gunnar Tepe speaks at ISET 2026
ISET 2026
The State of DCB Technology in 2026: Where Are We Going?
03/31/2026
Gunnar Tepe, MD
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest...
03/31/2026
Vascular Disease Management
Dr Jacques Busquet speaks at ISET 2026.
ISET 2026
The Mystery of Post-EVAR Endotension
03/26/2026
Jacques Busquet, MD
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned...
03/26/2026
Vascular Disease Management
Dr Sanjay Misra speaks at ISET 2026
ISET 2026
Renal Denervation for Refractory Hypertension: Indications, Data, and Outcomes
03/25/2026
Sanjay Misra, MD, FSIR, FAHA, FACR
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist...
03/25/2026
Vascular Disease Management

Conference Coverage

VDM logo
SIO 2026
Abstracts Presented at SIO 2026 Highlight Advances in Y-90 Radioembolization
03/02/2026
Laura Simson, MA
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts...
03/02/2026
Vascular Disease Management
Society of Interventional Oncology logo
SIO 2026
SIO 2026 Spotlights Pain Palliation, Pressure Monitoring, Technological Innovation
02/06/2026
Laura Simson, MA
Highlights from SIO 2026, the Society of Interventional Oncology Annual Scientific Meeting.
Highlights from SIO 2026, the Society of Interventional Oncology Annual Scientific Meeting.
Highlights from SIO 2026, the...
02/06/2026
Vascular Disease Management
CIO logo
CIO 2025
Current Status of Histotripsy: Liver, Renal, and Beyond
01/29/2026
Laura Simson, MA
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal...
01/29/2026
Vascular Disease Management
CIO 2025
Radiation Therapy Alone vs Radiation Therapy Plus Radiofrequency Ablation/Vertebral Augmentation for Painful Spine Metastasis: A Phase 2 Randomized Controlled Trial
01/15/2026
Brian J. Schiro, MD
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the...
01/15/2026
Vascular Disease Management
Stumetz headshot
CIO 2025
Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes
11/25/2025
Kyle S. Stumetz, DO; Laura Simson, MA
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the...
11/25/2025
Vascular Disease Management
CIO image
CIO 2025
Y90: Year in Review
11/12/2025
Laura Simson, MA
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J....
11/12/2025
Vascular Disease Management
RGandhi
CIO 2025
Y90 Dosimetry Pre-Conference Training for Interventional Oncology in Miami Beach
09/26/2025
Ripal Gandhi, MD
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium...
09/26/2025
Vascular Disease Management
BO_IP_headshots
SIO 2025
An Exciting Frontier: The Rise of Robotics in Interventional Oncology
01/29/2025
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO...
01/29/2025
Vascular Disease Management
AJ Gunn, MD, University of Alabama at Birmingham
CIO 2024
Percutaneous Renal Ablation
10/17/2024
Andrew J. Gunn, MD
AJ Gunn, MD, discusses percutaneous renal ablation.
AJ Gunn, MD, discusses percutaneous renal ablation.
AJ Gunn, MD, discusses...
10/17/2024
Vascular Disease Management
Altan Ahmed, MD, Moffitt Cancer Center
CIO 2024
Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma
10/16/2024
Altan Ahmed, MD, discusses percutaneous hepatic perfusion as a treatment option for patients with metastatic uveal melanoma.
Altan Ahmed, MD, discusses percutaneous hepatic perfusion as a treatment option for patients with metastatic uveal melanoma.
Altan Ahmed, MD, discusses...
10/16/2024
Vascular Disease Management
VDM logo
SIO 2026
Abstracts Presented at SIO 2026 Highlight Advances in Y-90 Radioembolization
03/02/2026
Laura Simson, MA
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts presented at Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting reflect the expanding role of transarterial radioembolization and radiation segmentectomy across a spectrum of hepatic and...
The yttrium-90 (Y-90) abstracts...
03/02/2026
Vascular Disease Management
Society of Interventional Oncology logo
SIO 2026
SIO 2026 Spotlights Pain Palliation, Pressure Monitoring, Technological Innovation
02/06/2026
Laura Simson, MA
Highlights from SIO 2026, the Society of Interventional Oncology Annual Scientific Meeting.
Highlights from SIO 2026, the Society of Interventional Oncology Annual Scientific Meeting.
Highlights from SIO 2026, the...
02/06/2026
Vascular Disease Management
CIO logo
CIO 2025
Current Status of Histotripsy: Liver, Renal, and Beyond
01/29/2026
Laura Simson, MA
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal Mendiratta-Lala presented an in-depth review of the current clinical status of histotripsy for the liver and emerging nonhepatic applications.
At CIO 2025, Dr Mishal...
01/29/2026
Vascular Disease Management
CIO 2025
Radiation Therapy Alone vs Radiation Therapy Plus Radiofrequency Ablation/Vertebral Augmentation for Painful Spine Metastasis: A Phase 2 Randomized Controlled Trial
01/15/2026
Brian J. Schiro, MD
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the Best Poster Award at CIO 2025, discusses his study on radiation therapy vs radiation therapy plus radiofrequency ablation.
Brian Schiro, MD, winner of the...
01/15/2026
Vascular Disease Management
Stumetz headshot
CIO 2025
Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes
11/25/2025
Kyle S. Stumetz, DO; Laura Simson, MA
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the 2025 CIO Young Investigator Award, discusses his study, “Absorbable Gelatin Hydrodissection in Oncologic Thermal Ablations: Initial Outcomes.”
Kyle S. Stumetz, winner of the...
11/25/2025
Vascular Disease Management
CIO image
CIO 2025
Y90: Year in Review
11/12/2025
Laura Simson, MA
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J. Lewandowski presented “Y90: Year in Review,” a comprehensive update on advances in yttrium-90 (Y-90) radioembolization across hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic liver disease.
At CIO 2025, Dr Robert J....
11/12/2025
Vascular Disease Management
RGandhi
CIO 2025
Y90 Dosimetry Pre-Conference Training for Interventional Oncology in Miami Beach
09/26/2025
Ripal Gandhi, MD
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium on Clinical Interventional Oncology (CIO), Ripal Gandhi, MD, speaks about the Y90 Dosimetry Pre-Conference, an immersive workshop designed to deepen clinicians’ expertise in Y90 radioembolization dosimetry.
In advance of the 2025 Symposium...
09/26/2025
Vascular Disease Management
BO_IP_headshots
SIO 2025
An Exciting Frontier: The Rise of Robotics in Interventional Oncology
01/29/2025
Bruno C. Odisio, MD, PhD, FSIR, FCIRSE; Iwan Paolucci, PhD
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO conference, Dr Bruno C. Odisio, MD, PhD, FSIR, FCIRSE, and Iwan Paolucci, PhD, spoke with VDM about their upcoming sessions on Robotics, Navigation, Guidance, and Confirmation.
In advance of the 2025 SIO...
01/29/2025
Vascular Disease Management
AJ Gunn, MD, University of Alabama at Birmingham
CIO 2024
Percutaneous Renal Ablation
10/17/2024
Andrew J. Gunn, MD
AJ Gunn, MD, discusses percutaneous renal ablation.
AJ Gunn, MD, discusses percutaneous renal ablation.
AJ Gunn, MD, discusses...
10/17/2024
Vascular Disease Management
Altan Ahmed, MD, Moffitt Cancer Center
CIO 2024
Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma
10/16/2024
Altan Ahmed, MD, discusses percutaneous hepatic perfusion as a treatment option for patients with metastatic uveal melanoma.
Altan Ahmed, MD, discusses percutaneous hepatic perfusion as a treatment option for patients with metastatic uveal melanoma.
Altan Ahmed, MD, discusses...
10/16/2024
Vascular Disease Management

Stay in the Know

Vascular Disease Management Newsletter

News

Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management
Histotripsy
Histotripsy Adoption in Interventional Oncology Presents Opportunities and Challenges in the United Kingdom
06/03/2026
Laura Simson, MA
06/03/2026
Vascular Disease Management
Clinical Trials
Surrogate Endpoints Remain a Challenge in Interventional Oncology Trials
05/12/2026
Laura Simson, MA
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined the strengths and limitations of surrogate endpoints in interventional oncology clinical trials.
A 2026 review article examined...
05/12/2026
Vascular Disease Management
Novel Local Therapies
Pulsed Electric Field Ablation Plus SBRT Preserves Quality of Life in Lung Tumors
04/13/2026
Laura Simson, MA
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study evaluated the impact of a novel combination of pulsed electric field ablation and stereotactic body radiation therapy on health-related quality of life and pulmonary function in patients with oligometastatic or...
A prospective pilot study...
04/13/2026
Vascular Disease Management
AML TUMORS
Fluidx Medical Announces First Patient Treated with Novel Embolic Gel
04/01/2026
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. 
Gel embolic device designed to...
04/01/2026
Vascular Disease Management
VDM logo
Analysis
Artificial Intelligence Advances in Interventional Oncology: Year in Review
02/23/2026
Laura Simson, MA
02/23/2026
Vascular Disease Management
VDM logo
News
Medicare Updates to Reshape Interventional Oncology Reimbursement in 2026
11/11/2025
Laura Simson, MA
11/11/2025
Vascular Disease Management
Stroke Interventions
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
07/17/2026
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026...
07/17/2026
Vascular Disease Management
Liver Tumor Ablation
First Meta-analysis Supports Histotripsy for Liver Tumor Ablation
07/14/2026
Laura Simson, MA
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high...
07/14/2026
Vascular Disease Management
Radiation Safety
Landmark Multi-Society Consensus Signals New Era in Occupational Radiation Safety; Rampart Positioned to Accelerate Adoption of Lead-Free Enhanced Radiation Protection
07/14/2026
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026...
07/14/2026
Vascular Disease Management
GPX Embolic Device
GPX® Embolic Device Meets Primary Endpoints in an Investigational Device Exemption (IDE) Pivotal Trial
07/14/2026
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx Medical Technology, Inc. announced the positive results from the Investigational Device Exemption (IDE) pivotal clinical trial evaluating the GPX Embolic Device. In the 114 patients that were treated in the trial,...
Salt Lake City (UT) – Fluidx...
07/14/2026
Vascular Disease Management
Transarterial Chemoembolization
STRIDE-Based Regimens Plus TACE Improve Outcomes vs TACE Alone in Embolization-Eligible Hepatocellular Carcinoma
07/13/2026
Stephanie Holland
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3 EMERALD-3 trial demonstrated that combining STRIDE-based immunotherapy with TACE, with or without lenvatinib, significantly improved progression-free survival compared with TACE alone, supporting a potential new...
Results from the phase 3...
07/13/2026
Vascular Disease Management
Peripheral Intervention
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease
07/09/2026
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36 months.
Data from one of the first...
07/09/2026
Cath Lab Digest
Thrombectomy for Stroke
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
07/07/2026
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer...
ALAMEDA, Calif. - Penumbra, Inc....
07/07/2026
Cath Lab Digest
Embolization
Fluidx Announces Continued Clinical Success with ULTRA Embolic Gel
07/02/2026
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02, 2026 — Fluidx Medical Technology, Inc. today announced that its ULTRA Embolic Device continues to see clinical success and was most recently used to treat a large, right-sided renal cell carcinoma (RCC) tumor at...
SALT LAKE CITY, UT — July 02,...
07/02/2026
Vascular Disease Management
BTK Treatment for CLTI
Medical University of Graz Enrolls First Patient in DEEPER CHALLENGE Trial Evaluating Spur® Peripheral Retrievable Scaffold System in a Select CLTI Cohort
07/02/2026
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow...
07/02/2026
Vascular Disease Management
Reperfusion Catheters
Now in Europe: RED™ 72 SILVER LABEL
06/30/2026
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
The RED 72 SILVER LABEL devices are reperfusion catheters designed for acute ischemic stroke. Direct aspiration with RED 72 SILVER LABEL can provide a fast, frontline option for acute ischemic stroke. The COMPASS Trial has shown...
The RED 72 SILVER LABEL...
06/30/2026
Vascular Disease Management

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use